Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Now accepting nominations for the Fierce Innovation Awards - Submit your application today
Attovia Therapeutics
Biotech
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Attovia plans to use the IPO haul to kick off two large ph. 2 studies for ATTO-1310, a biologic that blocks the itch-inducing interleukin-31.
Darren Incorvaia
Aug 5, 2026 7:00am
Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Jul 30, 2026 8:57am
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Jul 15, 2026 4:09am
